期刊文献+

LC-MS/MS法测定人血浆中地氯雷他定及其代谢产物3-羟基地氯雷他定的浓度 被引量:4

LC-MS/MS determination of desloratadine and its metabolite 3-hydroxydesloratadine in human plasma
下载PDF
导出
摘要 目的:建立 LC-MS/MS 法测定人血浆中地氯雷他定及其主要代谢产物3-羟基地氯雷他定的浓度。方法:血浆样品经碱化后用乙醚提取,采用液相色谱-质谱联用法检测。色谱条件为分析柱 CAPCELL PAK C_(18)(50 mm×2.0 mm,5 μm),预柱Octadecyl C_(18)(4.0 mm×3.0 mm);流动相:甲醇-乙腈-5 mmol·L^(-1)甲酸铵水溶液(30:20:50);流速0.2 mL·min^(-1);柱温40℃;进样量10 μL。质谱条件为电喷雾离子源(ESI),正离子扫描;选择性监测质荷比(m/z)为311.1/259.1(地氯雷他定),327.1/275.1(3-羟基地氯雷他定),315.1/263.1(D_4-地氯雷他定,内标),331.1/279.1(D_4-3-羟基地氯雷他定,内标)带正电荷的分子离子峰。结果:地氯雷他定、3-羟基地氯雷他定的线性范围均为0.05~10.0 ng·mL^(-1),定量下限均为0.05 ng·mL^(-1),批内、批间 RSD 均小于10%。结论:该方法简便,灵敏度高,专属性强,可用于地氯雷他定及其代谢产物的临床药动学和生物等效性研究。 Objective: To develop an LC - MS/MS method for determination of desloratadine and its metabolite 3 - hydroxy desloratadine in human plasma. Methods:Plasma samples were basified by NaOH and extracted by ether. The concentrations of desloratadine and its metabolite 3 -hydroxy desloratadine were determined by LC -MS/MS. LC :Use CAPCELL PAK C 18 (50 mm × 2. 0 mm,5 μm) column with preliminary column Octadecyl C 18 (4. 0 mm × 3.0 m) , the mobile phase consisted of methanol - acetonitrile - 5 mmol · L^ - 1 ammonium formate ( 30: 20:50 ) , the flow rate was 0. 2 mL·min^- 1 ; column temperature was 40 ℃. MS : Electrospray ionization source was applied and operated in positive ion mode. Selected ion mass (m/z) 311.1/259. 1 (desloratadine) ,327.1/275.1 (3 -hydroxy desloratadine) ,315. 1/263.1 (D4 -desloratadine ,internal standard) ,331.1/279. 1 (D4 -3 -hydroxy desloratadine, internal standard) were be monitored to quantify. Results:The linear calibration curve of desloratadine and 3 - hydroxy desloratadine were both obtained over the concentration range of 0. 05 - 10. 0 ng · mL^- 1, the lowest limit of quantitative were both 0. 05 ng · mL^-1 ;within -batch RSD and between -batch RSD were less than 10%. Conclusion:The method is proved to be simple, sensitive and specific. Therefore it can be used for clinical pharmacokinetic studies of desloratadine and its metabolite 3 -hydroxy desloratadine in human plasma.
出处 《药物分析杂志》 CAS CSCD 北大核心 2007年第6期805-808,共4页 Chinese Journal of Pharmaceutical Analysis
关键词 地氯雷他定 3-羟基地氯雷他定 LC—MS/MS desloratadine 3 - hydroxy desloratadine LC - MS/MS
  • 相关文献

参考文献3

二级参考文献19

  • 1Anthes JC, Richard C, West RE, et al. Functional characterization of desloratadine and other antihistamines in a Chinese Hamster Ovary (CHO) cell line that expresses the cloned human bronchial smooth muscle cells ( HBSMC ). J Allergy Clin Immunol, 2000,104 (1Pt2):S385.
  • 2Kreutner W, Hey JA, Anthes J, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine HI receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung, 2000, 50(4) :345-352.
  • 3Cardelus I, Anton F, Beleta J, et al. Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle. Eur J Pharmacol, 1999, 374(2) :249-254.
  • 4Bayram H, Devalia JL, Khair OA,et al. Effect of loratadine on nitrogen dioxide-induced changes in electrical resistance and release of inflammatory mediators from cultured human bronchial epithelial cells. J Allergy Clin Immunol, 1999, 104(1) :93-99.
  • 5Kleine-Tebbe J, Josties C, Frank G, et al. Inhibition of IgE- and nonIgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine. J Allergy Clin Immunol, 1994, 93(2) :494-500.
  • 6Kreutner W, Hey JA, Chiu P, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects. Arzneimittelforschung, 2000, 50 (5) :441-448.
  • 7Banfield C, Padhi D, Glue P, et al. Electrocardiographic effects of multiple high doses of desloratadine. J Allergy Clin Immunol, 2000,104(1 Pt2) :S383.
  • 8Hey J, Anthes J, Barnett A, et al. Preclinical cardiovascular and CNS safety profile of desloratadine, a selective and nonsedating histamine H1-receptor antagonist. J Allergy Clin Immunol,2000,104(1Pt2):S383.
  • 9Vuurman E, Ramaekers JG, Rikken G, et al. Desloratadine does not impair actual driving performance: a 3-way crossover comparison with diphenhydramin and placbo . Allergy, 2000,55 ( Suppl 63 ): 263 -264.
  • 10Herron JM,Padhi D,Affrime MB, et al. Dose-proportionality, linearity, and pharmackinetics of desloratadine in health y adults. J Allergy Clin Immunol, 2000,104 (1 Pt 2) :S385.

共引文献12

同被引文献14

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部